Alexander D. Cross
Keine laufenden Positionen mehr
Profil
Alexander D.
Cross served as President & CEO of Zoecon Corp.
from 1979 to 1985.
He was also Chairman & CEO of CytoPharm, Inc. Additionally, he served as a Director at MDRNA, Inc. and Ligand Pharmaceuticals, Inc. and as an Independent Director at Atossa Therapeutics, Inc. He was a Principal at NDA Partners LLC from 2003 to 2018.
Dr. Cross received his undergraduate and doctorate degrees from The University of Nottingham.
Ehemalige bekannte Positionen von Alexander D. Cross
| Unternehmen | Position | Ende |
|---|---|---|
NDA Partners LLC
 NDA Partners LLC Miscellaneous Commercial ServicesCommercial Services NDA Partners LLC provides strategy consulting services. It also provides a comprehensive range of services across the product development life cycle for drugs, biologics, biosimilars, vaccines, generics, devices, combination products and diagnostics. The company was founded by Carl C. Peck and Earle Martin and is headquartered in Annapolis, MD. | Corporate Officer/Principal | 11.06.2018 |
| ATOSSA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 31.12.2013 |
MDRNA, Inc.
 MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | Direktor/Vorstandsmitglied | 20.05.2009 |
| LIGAND PHARMACEUTICALS INCORPORATED | Direktor/Vorstandsmitglied | 17.03.2007 |
CytoPharm, Inc.
 CytoPharm, Inc. Pharmaceuticals: MajorHealth Technology CytoPharm, Inc. engages in the biopharmaceutical industry. The company specializes in protein drug development. It focuses on producing human natural cytokines such as interferon, interleukin and chemokine as modulators of human immune system. The products can be utilized in single or cocktail treatment model for chronic virus hepatitis, various oncology diseases, virus infection and autoimmune diseases. The company was founded on February 12, 2003 and is headquartered in Taipei, Taiwan. | Vorsitzender | 01.08.2006 |
Ausbildung von Alexander D. Cross
| The University of Nottingham | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| ATOSSA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | Commercial Services |
NDA Partners LLC
NDA Partners LLC Miscellaneous Commercial ServicesCommercial Services NDA Partners LLC provides strategy consulting services. It also provides a comprehensive range of services across the product development life cycle for drugs, biologics, biosimilars, vaccines, generics, devices, combination products and diagnostics. The company was founded by Carl C. Peck and Earle Martin and is headquartered in Annapolis, MD. | Commercial Services |
CytoPharm, Inc.
CytoPharm, Inc. Pharmaceuticals: MajorHealth Technology CytoPharm, Inc. engages in the biopharmaceutical industry. The company specializes in protein drug development. It focuses on producing human natural cytokines such as interferon, interleukin and chemokine as modulators of human immune system. The products can be utilized in single or cocktail treatment model for chronic virus hepatitis, various oncology diseases, virus infection and autoimmune diseases. The company was founded on February 12, 2003 and is headquartered in Taipei, Taiwan. | Health Technology |
| Zoecon Corp. |
